In addition to Berenberg Bank, Moderna also received a Hold from HSBC’s Yifeng Liu in a report issued yesterday. However, on the same day, Piper Sandler maintained a Buy rating on Moderna ...
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness reflects worries over the company’s path back to ...
On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $39.77 which represents a decrease of $-2.37 or -5.62% from the prior close of $42.14. The stock opened at $42.05 and touched a ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $84.0, a ...
Short interest for healthcare stocks in S&P 500 stayed flat in October vs. September, while Moderna continued to be most shorted stock of the month. The average short interest for S&P 500 Health ...
On Friday, Moderna Inc (MRNA) stock saw a decline, ending the day at $46.83 which represents a decrease of $-3.45 or -6.86% from the prior close of $50.28. The stock opened at $50.42 and touched a low ...
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback